.jpg)
.png)
All
The NLA’s USAGE Campaign, which launched in 2012 as a joint initiative by the NLA, Kowa Pharmaceuticals America and Eli Lilly & Co. has won five nationally renowned public relations awards. The USAGE Campaign, which involved the largest known cholesterol survey conducted in the U.S., was... more
The armamentarium for lipid-lowering pharmacotherapy is evolving. Though statins remain the cornerstone of treatment, and nearly all statins and ezetimibe are generic, recent and emerging therapies such as PCSK9 inhibitors, bempedoic acid, evinacumab, and inclisiran will pose significant challenges... more
Atherogenic lipoproteins play a critical role in the initiation and progression of vascular atherosclerosis, and decades of research have clearly demonstrated the benefits of lipid-lowering therapy for prevention of atherosclerotic cardiovascular disease (ASCVD) events. However, despite the... more
A new study finds that about a third of children, ages 9 to 11, have cholesterol levels considered borderline or high. Nearly one-third of children may have worrisome levels of cholesterol, putting them at risk for cardiovascular problems decades later, according to a new study. The study of... more
The 2015 Impact Factors were recently released and the Journal of Clinical Lipidology (JCL) saw yet another significant increase — from 3.904 (2014) to 4.906 (2015). The Journal is now ranked 23rd out of 253 journals in its category (pharmacology and... more
From Medical Xpress: Hereditary high blood cholesterol leads to premature heart disease. It is overlooked and untreated virtually worldwide—including in Europe. This is a major problem as the disease is dangerous for health. However, this disease is easy to diagnose and treat, according to... more
Discuss this article at www.lipid.org/lipidspan Cardiovascular risk stratification is imperfect. There are multiple formulas with receiver operator curve (ROC) values, a measure of discrimination between predicted events and nonevents varying from 0.7 to 0.8. There are multiple risk scores. The... more
Clinicians are constantly presented with data and results intended to influence the treatment they render to patients. However, in spite of the gravity of the consequences of treatment, we are often not supplied with appropriate and adequate data on which to base our judgment of effectiveness. Such... more
Thank you for participating in the 21 Day Challenge. Below please find your opportunity to reflect on today's activity. Note: Chapter and Reflection are the only mandatory fields, though the NLA hopes to collect participant demographic data for improvement of DEI within our organization. more